PDS Biotechnology Corporation

PDS, a clinical-stage biotech owns a novel nanotechnology platform vector that has demonstrated eradication of aggressive cancers in preclinical studies.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location North Brunswick, NJ, US
  • Currency USD
  • Founded 2007
  • Employees 4
  • Website pdsbiotech.com

Company Summary

PDS Biotechnology is an early stage biopharma company. PDS owns VersamuneTM, a novel and superior cancer immunotherapy platform nanotechnology, which has demonstrated eradication of aggressive tumors with low doses of the VersamuneTM based products.
The lead product is in Phase 1 clinical trials for treatment of HPV related cancers (CIN, cervical, oral).
In 2012 PDS granted Merck KGaA a license to use VersamuneTM in 2 specific cancer drugs.

Team

  • Benjamin Cowen
    VP Business Development

    Benjamin Cowen, PhD, MBA has over 15 years of pharma experience mostly at Merck.

  • Frank Bedu-Addo
    President & CEO

    Frank Bedu-Addo, PhD has over 15 years of senior management and drug development/manufacturing experience and in large and small companies including the Liposome Company (Elan) and Schering Plough. At Cardinal Health he was responsible for successful start-up and management of East Coast biotech operations. At KBI BioPharma as Vice President, he was responsible for start-up and management of all P&L, business and drug development operations.

  • Greg Conn
    CSO

    Gregory Conn, PhD has over 35 years of experience at Merck, Regeneron and Covance.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free